Giraldo-Gonzalez German Camilo, Roman-Gonzalez Alejandro, Cañas Felipe, Garcia Andres
Health Science Doctorate Program, Cardiology, Universidad de Caldas, Manizales 170001, Colombia.
Facultad de Medicina, Endocrinology Department, Universidad de Antioquia, Medellin 050010, Colombia.
Int J Mol Sci. 2025 May 9;26(10):4548. doi: 10.3390/ijms26104548.
Type 2 diabetes is a significant risk factor for cardiovascular disease, particularly coronary heart disease, heart failure, and diabetic cardiomyopathy. Diabetic cardiomyopathy, characterized by heart dysfunction in the absence of coronary artery disease or hypertension, is triggered by various mechanisms, including hyperinsulinemia, insulin resistance, and inflammation. At the cellular level, increased insulin resistance leads to an imbalance in lipid and glucose metabolism, causing oxidative stress, mitochondrial dysfunction, and excess production of reactive oxygen species (ROS). This disrupts normal heart function, leading to fibrosis, hypertrophy, and cardiac remodeling. In diabetic patients, the excessive accumulation of fatty acids, advanced glycation end products (AGEs), and other metabolic disturbances further contribute to endothelial dysfunction and inflammatory responses. This inflammatory environment promotes structural damage, apoptosis, and calcium-handling abnormalities, resulting in heart failure. Additionally, diabetes increases the risk of arrhythmias, such as atrial fibrillation, which worsens cardiac outcomes. New insights into these molecular mechanisms have led to improvements in diabetes management, focusing on mitigating complications and understanding the cellular processes involved. Recent therapeutic advances, such as SGLT-2 inhibitors, have shown promise in addressing the energy imbalance and cardiac dysfunction seen in diabetic cardiomyopathy, offering new hope for better cardiovascular outcomes.
2型糖尿病是心血管疾病的重要危险因素,尤其是冠心病、心力衰竭和糖尿病性心肌病。糖尿病性心肌病的特征是在没有冠状动脉疾病或高血压的情况下出现心脏功能障碍,它由多种机制引发,包括高胰岛素血症、胰岛素抵抗和炎症。在细胞水平上,胰岛素抵抗增加会导致脂质和葡萄糖代谢失衡,引起氧化应激、线粒体功能障碍以及活性氧(ROS)的过量产生。这会破坏正常的心脏功能,导致纤维化、肥大和心脏重塑。在糖尿病患者中,脂肪酸、晚期糖基化终产物(AGEs)的过度积累以及其他代谢紊乱会进一步导致内皮功能障碍和炎症反应。这种炎症环境会促进结构损伤、细胞凋亡和钙处理异常,从而导致心力衰竭。此外,糖尿病会增加心律失常的风险,如心房颤动,这会使心脏预后恶化。对这些分子机制的新认识已促使糖尿病管理得到改善,重点在于减轻并发症并了解其中涉及的细胞过程。最近的治疗进展,如钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂,已显示出有望解决糖尿病性心肌病中出现的能量失衡和心脏功能障碍问题,为改善心血管预后带来了新希望。